GSK
Income statement / Annual
Last year (2023), GSK plc's total revenue was $30.33 B,
an increase of 3.42% from the previous year.
In 2023, GSK plc's net income was $4.93 B.
See GSK plc’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$30.33 B
|
$29.32 B
|
$34.11 B
|
$34.10 B
|
$33.75 B
|
$30.82 B
|
$30.19 B
|
$27.89 B
|
$23.92 B
|
$23.01 B
|
| Cost of Revenue |
$9.08 B |
$9.55 B |
$11.60 B |
$11.70 B |
$11.86 B |
$10.24 B |
$10.34 B |
$9.29 B |
$8.85 B |
$7.32 B |
| Gross Profit |
$21.25 B |
$19.77 B |
$22.51 B |
$22.40 B |
$21.89 B |
$20.58 B |
$19.84 B |
$18.60 B |
$15.07 B |
$15.68 B |
| Gross Profit Ratio |
0.7 |
0.67 |
0.66 |
0.66 |
0.65 |
0.67 |
0.66 |
0.67 |
0.63 |
0.68 |
| Research and Development
Expenses |
$6.22 B
|
$5.49 B
|
$5.28 B
|
$5.10 B
|
$4.57 B
|
$3.89 B
|
$4.48 B
|
$3.63 B
|
$3.56 B
|
$3.45 B
|
| General & Administrative
Expenses |
$9.39 B
|
$8.37 B
|
$10.98 B
|
$11.46 B
|
$11.40 B
|
$9.92 B
|
$9.67 B
|
$9.37 B
|
$9.23 B
|
$8.25 B
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.38 B
|
$1.35 B
|
$1.27 B
|
$1.06 B
|
$671.00 M
|
| Selling, General &
Administrative Expenses |
$9.39 B
|
$8.37 B
|
$10.98 B
|
$11.46 B
|
$11.40 B
|
$9.92 B
|
$9.67 B
|
$9.37 B
|
$9.23 B
|
$8.25 B
|
| Other Expenses |
-$184.00 M |
-$523.00 M |
$57.00 M |
-$1.94 B |
-$1.04 B |
-$292.00 M |
-$365.00 M |
-$421.00 M |
$7.72 B |
-$319.00 M |
| Operating Expenses |
$15.02 B |
$13.34 B |
$16.31 B |
$14.61 B |
$14.93 B |
$15.10 B |
$15.76 B |
$16.00 B |
$12.46 B |
$12.09 B |
| Cost And Expenses |
$23.58 B |
$22.89 B |
$27.91 B |
$26.32 B |
$26.79 B |
$25.34 B |
$26.10 B |
$25.29 B |
$21.32 B |
$19.41 B |
| Interest Income |
$40.00 M |
$76.00 M |
$28.00 M |
$44.00 M |
$98.00 M |
$81.00 M |
$65.00 M |
$72.00 M |
$104.00 M |
$68.00 M |
| Interest Expense |
$775.00 M |
$879.00 M |
$784.00 M |
$892.00 M |
$912.00 M |
$798.00 M |
$734.00 M |
$736.00 M |
$757.00 M |
$727.00 M |
| Depreciation &
Amortization |
$2.29 B
|
$2.15 B
|
$2.12 B
|
$2.35 B
|
$2.33 B
|
$1.86 B
|
$1.92 B
|
$1.77 B
|
$1.86 B
|
$2.03 B
|
| EBITDA |
$9.08 B
|
$8.60 B
|
$7.76 B
|
$8.10 B
|
$9.43 B
|
$9.35 B
|
$8.64 B
|
$7.06 B
|
$4.18 B
|
$5.48 B
|
| EBITDA Ratio |
0.3 |
0.3 |
0.26 |
0.25 |
0.3 |
0.24 |
0.24 |
0.16 |
0.51 |
0.25 |
| Operating Income Ratio
|
0.22
|
0.22
|
0.18
|
0.25
|
0.21
|
0.18
|
0.14
|
0.09
|
0.43
|
0.16
|
| Total Other
Income/Expenses Net |
-$681.00 M
|
-$805.00 M
|
-$758.00 M
|
-$809.00 M
|
-$740.00 M
|
-$683.00 M
|
-$562.00 M
|
-$659.00 M
|
$204.00 M
|
-$629.00 M
|
| Income Before Tax |
$6.06 B |
$5.63 B |
$3.60 B |
$5.17 B |
$6.22 B |
$4.80 B |
$3.53 B |
$1.94 B |
$10.53 B |
$2.97 B |
| Income Before Tax Ratio
|
0.2
|
0.19
|
0.15
|
0.21
|
0.18
|
0.16
|
0.12
|
0.07
|
0.44
|
0.13
|
| Income Tax Expense |
$756.00 M |
$707.00 M |
$83.00 M |
$67.00 M |
$953.00 M |
$754.00 M |
$1.36 B |
$877.00 M |
$2.15 B |
$137.00 M |
| Net Income |
$4.93 B |
$14.96 B |
$4.39 B |
$5.75 B |
$4.65 B |
$3.62 B |
$1.53 B |
$912.00 M |
$8.42 B |
$2.76 B |
| Net Income Ratio |
0.16 |
0.51 |
0.18 |
0.24 |
0.14 |
0.12 |
0.05 |
0.03 |
0.35 |
0.12 |
| EPS |
1.2 |
7.43 |
2.74 |
2.89 |
2.35 |
1.84 |
0.78 |
0.47 |
4.36 |
1.43 |
| EPS Diluted |
1.2 |
7.32 |
2.71 |
2.85 |
2.32 |
1.82 |
0.78 |
0.46 |
4.31 |
1.42 |
| Weighted Average Shares
Out |
$4.11 B
|
$2.01 B
|
$1.60 B
|
$1.99 B
|
$1.98 B
|
$1.97 B
|
$1.95 B
|
$1.94 B
|
$1.93 B
|
$1.92 B
|
| Weighted Average Shares
Out Diluted |
$4.11 B
|
$2.04 B
|
$1.62 B
|
$2.02 B
|
$2.01 B
|
$1.99 B
|
$1.98 B
|
$1.96 B
|
$1.96 B
|
$1.95 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
